Who are CSII followed by Lina+MET's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/csii-followed-by-lina-met.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CSII followed by Lina+MET — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CSII followed by Lina+MET (CSII followed by Lina+MET) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin therapy combined with DPP-4 inhibitor and biguanide. Area: Endocrinology / Diabetes.

marketed Insulin therapy combined with DPP-4 inhibitor and biguanide Insulin receptor (CSII); DPP-4 enzyme (linagliptin); mitochondrial glycerophosphate dehydrogenase (metformin) Endocrinology / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

CSII followed by Lina+MET (CSII followed by Lina+MET) — Sun Yat-sen University. CSII (continuous subcutaneous insulin infusion) followed by a combination of a DPP-4 inhibitor (linagliptin) and metformin improves glycemic control through sustained insulin delivery and enhanced incretin-based glucose regulation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CSII followed by Lina+MET TARGET	CSII followed by Lina+MET	Sun Yat-sen University	marketed	Insulin therapy combined with DPP-4 inhibitor and biguanide	Insulin receptor (CSII); DPP-4 enzyme (linagliptin); mitochondrial glycerophosphate dehydrogenase (metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin therapy combined with DPP-4 inhibitor and biguanide class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CSII followed by Lina+MET — Competitive Intelligence Brief. https://druglandscape.com/ci/csii-followed-by-lina-met. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab